Patents Assigned to Neuralab Limited
  • PREVENTION AND TREATMENT OF AMYLOIDOGENIC DISEASE
    Publication number: 20090297511
    Abstract: The invention provides compositions and methods for treatment of amyloidogenic diseases. Such methods entail administering an agent that induces a beneficial immune response against an amyloid deposit in the patient. The methods are particularly useful for prophylactic and therapeutic treatment of Alzheimer's disease. In such methods, a suitable agent is A? peptide, active fragments thereof or an antibody thereto.
    Type: Application
    Filed: December 4, 2008
    Publication date: December 3, 2009
    Applicant: Neuralab Limited
    Inventor: Dale B. Schenk
  • Humanized antibodies that recognize beta amyloid peptide
    Patent number: 7189819
    Abstract: The invention provides improves agents and methods for treatment of diseases associated with amyloid deposits of A? in the brain of a patient. Preferred agents include humanized antibodies.
    Type: Grant
    Filed: December 6, 2001
    Date of Patent: March 13, 2007
    Assignees: Wyeth, Neuralab Limited
    Inventors: Guriq Basi, Jose William Saldanha
  • Humanized antibodies that recognize beta amyloid peptide
    Patent number: 7179892
    Abstract: The invention provides improved agents and methods for treatment of diseases associated with amyloid deposits of A? in the brain of a patient. Preferred agents include humanized antibodies.
    Type: Grant
    Filed: March 12, 2003
    Date of Patent: February 20, 2007
    Assignees: Neuralab Limited, Wyeth
    Inventors: Guriq Basi, Jose William Saldanha
  • Humanized antibodies that recognize beta amyloid peptide
    Publication number: 20060280743
    Abstract: The invention provides improved agents and methods for treatment of diseases associated with amyloid deposits of A? in the brain of a patient. Preferred agents include humanized antibodies.
    Type: Application
    Filed: April 28, 2006
    Publication date: December 14, 2006
    Applicants: Neuralab Limited, Wyeth
    Inventors: Guriq Basi, Jose Saldanha
  • Prevention and treatment of amyloidogenic disease
    Publication number: 20060121038
    Abstract: The invention provides improved agents and methods for treatment of diseases associated with amyloid deposits of A? in the brain of a patient. Such methods entail administering agents that induce a beneficial immunogenic response against the amyloid deposit. The methods are useful for prophylactic and therapeutic treatment of Alzheimer's disease. Preferred agents including N-terminal fragments of A? and antibodies binding to the same.
    Type: Application
    Filed: July 12, 2004
    Publication date: June 8, 2006
    Applicant: Neuralab Limited
    Inventors: Dale Schenk, Frederique Bard, Theodore Yednock
  • Prevention and treatment of amyloidogenic disease
    Patent number: 7014855
    Abstract: The invention provides compositions and methods for treatment of amyloidogenic diseases. Such methods entail administering an agent that induces a beneficial immune response against an amyloid deposit in the patient. The methods are particularly useful for prophylactic and therapeutic treatment of Alzheimer's disease. In such methods, a suitable agent is A? peptide or an antibody thereto.
    Type: Grant
    Filed: March 31, 2004
    Date of Patent: March 21, 2006
    Assignee: Neuralab Limited
    Inventor: Dale B. Schenk
  • Prevention and treatment of amyloidogenic disease
    Publication number: 20060034858
    Abstract: The invention provides compositions and methods for treatment of amyloidogenic diseases. Such methods entail administering an agent that induces a beneficial immune response against an amyloid deposit in the patient. The methods are particularly useful for prophylactic and therapeutic treatment of Alzheimer's disease. In such methods, a suitable agent is A? peptide or an antibody thereto.
    Type: Application
    Filed: October 7, 2005
    Publication date: February 16, 2006
    Applicant: Neuralab Limited
    Inventor: Dale Schenk
  • Prevention and treatment of amyloidogenic disease
    Publication number: 20060029611
    Abstract: The invention provides compositions and methods for treatment of amyloidogenic diseases. Such methods entail administering an agent that induces a beneficial immune response against an amyloid deposit in the patient. The methods are particularly useful for prophylactic and therapeutic treatment of Alzheimer's disease. In such methods, a suitable agent is A? peptide or an antibody thereto.
    Type: Application
    Filed: October 7, 2005
    Publication date: February 9, 2006
    Applicant: Neuralab Limited
    Inventor: Dale Schenk
  • Prevention and treatment of amyloidogenic disease
    Patent number: 6982084
    Abstract: The invention provides compositions and methods for treatment of amyloidogenic diseases. Such methods entail administering an agent that induces a beneficial immune response against an amyloid deposit in the patient. The methods are particularly useful for prophylactic and therapeutic treatment of Alzheimer's disease. In such methods, a suitable agent is A? peptide or an antibody thereto.
    Type: Grant
    Filed: March 31, 2004
    Date of Patent: January 3, 2006
    Assignee: NeuraLab Limited
    Inventor: Dale B. Schenk
  • Prevention and treatment of amyloidogenic disease
    Patent number: 6972127
    Abstract: The invention provides compositions and methods for treatment of amyloidogenic diseases. Such methods entail administering an agent that induces a beneficial immune response against an amyloid deposit in the patient. The methods are particularly useful for prophylactic and therapeutic treatment of Alzheimer's disease. In such methods, a suitable agent is A? peptide or an antibody thereto.
    Type: Grant
    Filed: September 2, 2004
    Date of Patent: December 6, 2005
    Assignee: Neuralab Limited
    Inventor: Dale B. Schenk
  • Prevention and treatment of amyloidogenic disease
    Publication number: 20050255122
    Abstract: The invention provides compositions and methods for treatment of amyloidogenic diseases. Such methods entail administering an agent that induces a beneficial immune response against an amyloid deposit in the patient. The methods are particularly useful for prophylactic and therapeutic treatment of Alzheimer's disease. In such methods, a suitable agent is A? peptide or an antibody thereto.
    Type: Application
    Filed: September 2, 2004
    Publication date: November 17, 2005
    Applicant: Neuralab Limited
    Inventor: Dale Schenk
  • Prevention and treatment of amyloidogenic disease
    Publication number: 20050249727
    Abstract: The invention provides compositions and methods for treatment of amyloidogenic diseases. Such methods entail administering an agent that induces a beneficial immune response against an amyloid deposit in the patient. The methods are particularly useful for prophylactic and therapeutic treatment of Alzheimer's disease. In such methods, a suitable agent is A? peptide, active fragments thereof or an antibody thereto.
    Type: Application
    Filed: August 20, 2004
    Publication date: November 10, 2005
    Applicant: Neuralab Limited
    Inventor: Dale Schenk
  • Prevention and treatment of amyloidogenic disease
    Patent number: 6962707
    Abstract: The invention provides compositions and methods for treatment of amyloidogenic diseases. Such methods entail administering an agent that induces a beneficial immune response against an amyloid deposit in the patient. The methods are particularly useful for prophylactic and therapeutic treatment of Alzheimer's disease. In such methods, a suitable agent is A? peptide or an antibody thereto.
    Type: Grant
    Filed: July 1, 2004
    Date of Patent: November 8, 2005
    Assignee: Neuralab Limited
    Inventor: Dale B. Schenk
  • Prevention and treatment of amyloidogenic disease
    Patent number: 6946135
    Abstract: The invention provides compositions and methods for treatment of amyloidogenic diseases. Such methods entail administering an agent that induces a beneficial immune response against an amyloid deposit in the patient. The methods are particularly useful for prophylactic and therapeutic treatment of Alzheimer's disease. In such methods, a suitable agent is A?, peptide or an antibody thereto.
    Type: Grant
    Filed: September 2, 2004
    Date of Patent: September 20, 2005
    Assignee: Neuralab Limited
    Inventor: Dale B. Schenk
  • Prevention and treatment of amyloidogenic disease
    Publication number: 20050191314
    Abstract: The invention provides compositions and methods for treatment of amyloidogenic diseases. Such methods entail administering an agent that induces a beneficial immune response against an amyloid deposit in the patient. The methods are particularly useful for prophylactic and therapeutic treatment of Alzheimer's disease. In such methods, a suitable agent is A? peptide or an antibody thereto.
    Type: Application
    Filed: April 15, 2005
    Publication date: September 1, 2005
    Applicant: Neuralab Limited
    Inventor: Dale Schenk
  • Prevention and treatment of amyloidogenic disease
    Publication number: 20050191292
    Abstract: The invention provides compositions and methods for treatment of amyloidogenic diseases. Such methods entail administering an agent that induces a beneficial immune response against an amyloid deposit in the patient. The methods are particularly useful for prophylactic and therapeutic treatment of Alzheimer's disease. In such methods, a suitable agent is A? peptide, active fragments thereof or an antibody thereto.
    Type: Application
    Filed: August 20, 2004
    Publication date: September 1, 2005
    Applicant: Neuralab Limited
    Inventor: Dale Schenk
  • Passive immunization of ASCR for prion disorders
    Patent number: 6936246
    Abstract: Disclosed are pharmaceutical compositions and methods for preventing or treating a number of amyloid diseases, including Alzheimer's disease, prion diseases, familial amyloid neuropathies and the like. The pharmaceutical compositions include immunologically reactive amounts of amyloid fibril components, particularly fibril-forming peptides or proteins. Also disclosed are therapeutic compositions and methods which use immune reagents that react with such fibril components.
    Type: Grant
    Filed: November 28, 2000
    Date of Patent: August 30, 2005
    Assignee: Neuralab Limited
    Inventor: Dale B. Schenk
  • Active immunization of AScr for prion disorders
    Patent number: 6923964
    Abstract: Disclosed are pharmaceutical compositions and methods for preventing or treating a number of amyloid diseases, including Alzheimer's disease, prion diseases, familial amyloid neuropathies and the like. The pharmaceutical compositions include immunologically reactive amounts of amyloid fibril components, particularly fibril-forming peptides or proteins. Also disclosed are therapeutic compositions and methods which use immune reagents that react with such fibril components.
    Type: Grant
    Filed: June 1, 2000
    Date of Patent: August 2, 2005
    Assignee: Neuralab Limited
    Inventor: Dale B. Schenk
  • Prevention and treatment of amyloidogenic disease
    Publication number: 20050163788
    Abstract: The invention provides compositions and methods for treatment of amyloidogenic diseases. Such methods entail administering an agent that induces a beneficial immune response against an amyloid deposit in the patient. The methods are particularly useful for prophylactic and therapeutic treatment of Alzheimer's disease. In such methods, a suitable agent is A? peptide or an antibody thereto.
    Type: Application
    Filed: September 2, 2004
    Publication date: July 28, 2005
    Applicant: Neuralab Limited
    Inventor: Dale Schenk
  • Prevention and treatment of amyloidogenic disease
    Publication number: 20050158304
    Abstract: The invention provides improved agents and methods for treatment of diseases associated with amyloid deposits of A? in the brain of a patient. Such methods entail administering agents that induce a beneficial immunogenic response against the amyloid deposit. The methods are useful for prophylactic and therapeutic treatment of Alzheimer's disease. Preferred agents including N-terminal fragments of A? and antibodies binding to the same.
    Type: Application
    Filed: July 12, 2004
    Publication date: July 21, 2005
    Applicant: Neuralab Limited
    Inventors: Dale Schenk, Frederique Bard, Theodore Yednock